Intelligent Bio Solutions (INBS) Non-Current Receivables (2021 - 2022)
Intelligent Bio Solutions' quarterly Non-Current Receivables came in at $1.1 million in Q4 2022, down 6.46% year-on-year from $1.2 million in Q4 2021, and up 4.39% quarter-over-quarter from $1.0 million in Q3 2022.
Intelligent Bio Solutions has reported Non-Current Receivables for 2 years, with the latest figure at $1.1 million in Q4 2022.
- For the quarter ending Q4 2022, Non-Current Receivables fell 6.46% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2022 stood at $1.1 million (down 6.46% YoY), and the FY2022 full-year result was $1.1 million, down 65.29% from the prior year.
- Non-Current Receivables for Q4 2022 stood at $1.1 million, up from $1.0 million in the prior quarter.
- The five-year high for Non-Current Receivables was $3.1 million in Q2 2021, with the low at $1.0 million in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 257.56 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Intelligent Bio Solutions | 13.61 Mn | 12.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.08 Mn |
| Sep 30, 2022 | 1.03 Mn |
| Jun 30, 2022 | 1.09 Mn |
| Mar 31, 2022 | 1.19 Mn |
| Dec 31, 2021 | 1.15 Mn |
| Sep 30, 2021 | 2.70 Mn |
| Jun 30, 2021 | 3.15 Mn |